Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
